Trial Profile
An Open-Label, Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 18 Sep 2023 Status changed from completed to discontinued early because of lack of efficacy.
- 21 Nov 2022 Status changed from active, no longer recruiting to completed.
- 01 Mar 2022 Planned End Date changed from 1 May 2021 to 1 May 2022.